For KRAS-mutant non-small cell lung cancer (NSCLC), a Phase II study (NCT01951690) evaluated defactinib, demonstrating improvements in progression-free survival across four cohorts. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.